We previously reported adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor (bFGF) as a new treatment for leg ischemia. This time, we tested this method on a swine myocardial ischemia model, seeking the possibility of its application for ischemic heart disease. An ameroid constrictor was placed around the proximal left circumflex branch of pigs to induce myocardial ischemia. Simultaneously, a skin section was harvested and fibroblasts were cultured. Fibroblasts were then infected with adenovirus vector containing a bFGF cDNA with a secretory signal sequence (bFGF group, n¼8) or a LacZ cDNA (control group, n¼8). At 28 days after constrictor implantation, 2.5 Â 10 6 fibroblasts were administered into each of the right and left coronary arteries. The injected fibroblasts accumulated in the myocardium without causing myocardial ischemia. Echocardiography, electromechanical mapping and coronary arteriography were conducted just before and 28 days after fibroblast injection, and regional left ventricular myocardial blood flow was measured 28 days after fibroblast injection. These evaluations revealed that the bFGF group exhibited significant development of collateral vessels and improvement of myocardial contraction in the ischemic area compared with the control group. We believe that this method is a promising treatment strategy for ischemic heart disease.
Introduction
Augmentation of collateral circulation is a promising treatment strategy for severe ischemic heart disease, and many procedures for collateral vessel development have been reported. One of the recent trends is local delivery of angiogenic growth factors, such as basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF), and several delivery systems of growth factors have been tested. [1] [2] [3] [4] We previously presented a new method for gene transfer of bFGF and showed excellent collateral vessel development in a rabbit hind limb ischemia model. 5 In our method, autofibroblasts adenovirally transduced with modified bFGF genes containing a secretory signal sequence are administered into the ischemic area through an intra-arterial catheter, are trapped in capillaries or arterioles, and secrete bFGF for several weeks. In the present study, we applied this method to a swine myocardial ischemia model and examined whether it improves myocardial perfusion and function, seeking to possible application for human ischemic heart disease.
Results

In vitro study
Cultured pig fibroblasts were infected with adenovirus vector containing modified human bFGF cDNA (bFGFfibroblast), and secretion of intact bFGF was assessed. Western blot analysis showed secreted bFGF in the culture medium of bFGF-fibroblast. Two forms of bFGF (18 and 22 kDa) were detected strongly between 4 and 21 days after infection ( Figure 1a ). In addition, 3 H-thymidine incorporation assay revealed significantly higher DNA synthesis activity of bFGF 4 and 7 days after infection than the control (Figure 1b) , indicating that the secreted bFGF was biologically active.
To examine the transduction efficiency, cultured fibroblasts were infected with adenovirus vector containing LacZ cDNA (LacZ-fibroblast). Almost all the fibroblasts stained positive with X-gal staining ( Figure 1c ) 4 days after infection, and the transduction efficiency was proved to be almost 100%.
In vivo study Echocardiography. To evaluate the effects on the global left ventricular (LV) function, the bFGF-fibroblasts (bFGF group, n¼8) or LacZ-fibroblasts (control group, n¼8) were injected into the coronary arteries of a swine myocardial ischemia model (refer to 'Animal model of myocardial ischemia'), and echocardiography was conducted before constrictor implantation, immediately before the fibroblast injection, and 28 days after the fibroblast injection. The bFGF group showed significantly greater improvement of the LV ejection fraction (EF) than the control group (Figure 2 ). The EF before constrictor implantation revealed no significant difference between the bFGF group and the control group (69.177.4 versus 65.378.3%, P¼0.34).
Electromechanical mapping (EMM).
To examine the regional LV function, EMM was conducted using the NOGA system (Version 4.0, Biosense, Tirat-HaCarmel, Israel) at the same timing as echocardiography. Global analysis showed significant intergroup difference in the improvement of local shortening (LS) (Fisher's combination of P-values in the nine sets of LS data was 37.1 [4w 2 (18, 0.05)¼34.8]; refer to 'Statistical analysis'). Subsequent regional analysis showed that the bFGF group revealed significantly greater improvement of LS in the posterior two segments and the lateral-midventricle segment of the LV than the control group (Table 1, Figure 3a, b) . Contrarily, the unipolar voltage (UpV) data showed no significant intergroup difference (Table 1) .
Coronary arteriography (CAG).
To evaluate the development of collateral vessels forwarded to the ischemic area (left circumflex branch area), right and left CAG was conducted at the same timing as echocardiography, and the Rentrop score was obtained. The bFGF group revealed significantly greater improvement in the Rentrop score of the right CAG than the control group (Figure 4a-c) , while no significant improvement was detected in that of the left CAG (Figure 4a) . Occlusion of the left circumflex branch (LCx) was confirmed in all pigs before fibroblast infusion (Figure 4d ).
Regional myocardial blood flow (RMBF). For the direct evaluation of the myocardial perfusion, RMBF was measured using the microsphere technique 28 days after the fibroblast injection. In the ischemic area, the bFGF group showed significantly higher blood flow rate than the control group, while there was no significant difference in the nonischemic area ( Figure 5 ).
Influence of intracoronary fibroblast injection. The influence of the intracoronary fibroblast injection was assessed. Although ST-T changes in the electrocardiogram were observed in six out of 16 (37.5%) pigs during or immediately after fibroblast injection, all these Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al changes spontaneously recovered within 3 min. In addition, plasma creatine kinase (CK)-MB was measured immediately before and 24 h after fibroblast injection, but no significant increase was observed after the fibroblast injection (6.071.3 versus 5.971.2 ng/ml, P¼0.94).
Distribution of injected fibroblasts. The distribution of the injected fibroblasts was assessed using the luciferase assay technique. At 2 h after injection, 65.573. 5% of the injected fibroblasts accumulated in the entire LV. In the nonischemic area, a significantly higher concentration of fibroblast accumulation was detected compared with that in the ischemic area ((6.971.2) Â 10 4 versus (2.070.8) Â 10 4 cells/1 g, P¼0.004). In addition, localization of the injected fibroblasts were histologically examined. LacZ-fibroblasts were administered to normal pigs, and the myocardial tissue of the inferior wall was harvested 7 days later. LacZ-fibroblasts were shown to lodge in capillaries and arterioles and not in the extravascular space ( Figure 6 ).
Time course study of in vivo bFGF expression and histology. To evaluate bFGF expression in vivo, the bFGF-fibroblasts were administered to four pig models, and the myocardium in the inferior wall was harvested 4, 7, 14, and 21 days after fibroblast administration. Western blot analysis revealed significant increase in bFGF concentration in the inferior wall between 4 and 14 days after fibroblast administration ( Figure 7 ). In all four pig models, tissue samples obtained from the inferior wall and the lateral wall did not reveal any clear evidence of myocardial infarction such as inflammatory cell infiltration, nuclear degeneration, or fibrosis.
Discussion
We tested our new treatment strategy, adenovirusmediated ex vivo gene transfer of bFGF, on a swine ischemic heart disease model and detected significant improvement of contraction and blood flow in the ischemic LV myocardium compared to the control.
According to the EMM results, UpV, which represents myocardial viability, revealed no significant intergroup difference. We therefore concluded that the angiogenic effect could fairly be compared using our animal model. Although the UpV in this study was rather low, it did not mean non-viability in the myocardium because the normal value of UpV in pigs used in this study was lower than that in humans (data not shown). On the other hand, LS, which represents myocardial contraction, significantly improved in the entire posterior wall and the midventricular part of the lateral wall after bFGFfibroblast injection compared to the control. These areas were compatible to the ischemic area where RMBF measurement detected significant increase of myocardial blood flow after bFGF-fibroblast injection compared to the control. Therefore, we concluded that the increase of blood flow in the ischemic myocardium because of the ex vivo gene transfer of bFGF improved myocardial mechanical function. In addition, the improvement of regional myocardial contraction probably led to the improvement of the EF after bFGF-fibroblast injection.
Significant collateral vessel development from the right coronary artery (RCA) to the LCx was detected with CAG after bFGF-fibroblast injection, and we thought this collateral circulation mainly contributed to the increase of myocardial blood flow in the ischemic area. As for the collateral sources, significant collateral vessel development was observed only from the RCA, Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al
and not from the left anterior descending artery (LAD).
Although the reason for this unequalness is unclear, the RCA is the main collateral source for the stenotic LCx also in humans according to our clinical experiences, probably because of anatomical reasons. Although we injected equal amounts of fibroblasts into each of the coronary arteries, hoping to demonstrate the clear angiogenic effects of our method, we now speculate that it is not always necessary to inject the same amount of fibroblasts into the LAD as into the RCA to obtain as much collateral vessel development as shown in this study.
It is important that electrocardiography and CK-MB measurement showed the safety of intracoronary fibroblast injection under the condition in this study, because cell injection would cause microembolism and would become a serious problem in clinical use. Luciferase assay showed that the injected fibroblasts highly effi- Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al ciently accumulated in the LV myocardium (65.573.5%) in this study, considering that not a few fibroblasts must have been trapped in the atrium or the right ventricle. Suzuki et al 6 administered skeletal myoblasts into rat coronary arteries and detected 50% of the cells, which is comparable to our result. Considering that the transduction efficiency was also very high (almost 100%), high efficiency of gene therapy can be anticipated from our method.
The fibroblasts retained in small vessels (capillaries or arterioles) for at least 7 days after administration, and the bFGF concentration in the myocardium kept increasing until 14 days after administration. These findings were similar to those in our previous rabbit study, 5 in which no fibrosis or other abnormal changes in the host tissue were observed. The optimal amount of fibroblasts to be injected and the optimal route of administration for clinical use should further be examined.
Our ex vivo method has several favorable features for clinical use. The injected bFGF-secreting fibroblasts survive for only few weeks in the host tissue as described above, decreasing the possibility of unexpected side effects because of unnecessarily prolonged secretion of growth factors. 7 And, if the angiogenic effect is insufficient, bFGF-secreting host-fibroblasts can be repeatedly administered without inducing humoral immune response. 5 In addition, the delivery system of fibroblasts is catheter-based and thus less invasive. Therefore, we believe this ex vivo method can easily be combined with the traditional catheter intervention for ischemic heart disease.
In summary, we tested the adenovirus-mediated ex vivo gene transfer of modified human bFGF on a swine myocardial ischemia model. The gene-transduced autofibroblasts could safely be administered into the coronary arteries and induce significant development of collateral vessels from the RCA to the LCx, thereby improving myocardial function. We believe this method is a promising treatment strategy for human ischemic heart disease.
Methods
Adenovirus vector
Replication-deficient recombinant adenovirus vectors containing a modified human bFGF gene with a Figure 5 Myocardial blood flow rate in the ischemic and the nonischemic areas 28 days after fibroblast injection. In the ischemic area, the bFGF group revealed significantly higher blood flow rate than the control group, while no significant difference was observed in the nonischemic area. Figure 6 The LacZ-fibroblast (arrow) was shown to retain in small vessels 7 days after administration. The scale bar is 10 mm. Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al secretory signal sequence of interleukin-2 (AxCAMAssbFGF) were constructed. 8, 9 Synthesized bFGF is secreted because of the signal sequence, and previous study 10 demonstrated that the secreted modified human bFGF was more stable than the original secreted human bFGF. The control vector was AxCALacZ, which varies from the Escherichia coli LacZ in the same expression unit. Furthermore, AxCAluc+ containing a recombinant luciferase gene (luc+) was used to assess the intramyocardial distribution of administered fibroblasts.
In vitro study
Cultured pig fibroblasts confluent in 60-mm dishes (passage 3) were infected with AxCAMAssbFGF at 20 PFU cell in 1 ml of Dulbecco's modified Eagle's minimum medium (DMEM, Gibco BRL, NY, USA) with 2% FBS (DMEM-2%). After 1-h incubation, the fibroblasts were washed twice with PBS, and cultured in 3 ml DMEM-2%. The medium was changed daily and was stored at 4, 7, 14, 21, and 28 days after infection. We excluded samples contaminated with residual virus by applying them to 293 cells and observing them for 14 days. Another set of pig fibroblasts was cultured in DMEM-2%, and daily-changed culture medium was stored as the control. Each medium (50 ml) was subjected to Western blot analysis using mouse monoclonal antibody against bovine bFGF (1:500, Upstate Biotechnology, NY, USA), and DNA synthesis activity of the secreted bFGF in the culture medium (100 ml) was evaluated by the incorporation of 3 H-thymidine into pig fibroblasts.
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These analyses were repeated at least twice.
Cultured pig fibroblasts were infected with A Â CALacZ in the same fashion as described above, and the fibroblasts were stained with X-gal staining 4 days after infection. The ratio of the fibroblasts expressing LacZ was obtained 8 h later.
Animal model of myocardial ischemia
We used a pig model of chronic myocardial ischemia induced with ameroid constrictors. All the protocols were approved by the Guide for Animal Experimentation, The University of Tokyo. Male LWD pigs (Saitama Experimental Animals Supply, Saitama, Japan) weighing 28-30 kg were anesthetized with ketamine hydrochloride (15 mg/kg, i.m.), pentobarbital sodium (10 mg/kg, i.v.), and vecuronium bromide (2 mg, i.v.), intubated, and ventilated with room air. Intra-arterial blood pressure and a limb lead electrocardiogram were monitored, and both ampicillin (500 mg, i.m.) and lidocaine (30 mg, i.v.) were administered before surgical procedures. After left thoracotomy, a metal-encased ameroid constrictor with 2.5 mm lumen (Research Instruments SW, CA, USA) was placed around the proximal zleft circumflex branch LCx. Simultaneously, a 10 Â 10 mm section of skin was obtained for fibroblast culture.
In total, 22 pigs were implanted with ameroid constrictors, and six of them died before being divided into the bFGF or the control group. The remaining 16 pigs survived and were randomly assigned to the two groups. Preliminary experiments using three pigs revealed the ameroid constrictors occluded the LCx within 28 days. In addition, occlusion of the LCx was confirmed using angiography in all pigs before fibroblast infusion.
Ex vivo gene transfer
Protocols are shown in Figure 8a . Fibroblasts were cultured from the resected skin to confluent in 100-mm dishes (three passages). At 27 days after constrictor implantation (Day 27), 5 Â 10 6 fibroblasts were infected with AxCAMAssbFGF (bFGF-fibroblast) or AxCALacZ (LacZ-fibroblast) at 20 PFU/cell and incubated for 24 h. On Day 28, under systemic heparinization (2000 U), a 6-French guiding catheter (Britetip JL4, Cordis Endovascular Systems, FL, USA) was inserted into the RCA via the right common carotid artery, and a thin infusion catheter (Transit 2, Cordis Endovascular Systems) was introduced through the guiding catheter into the RCA and positioned at 20 mm distal to the orifice. Subsequently, 2.5 Â 10 6 bFGF-fibroblast (n¼8) or LacZ-fibroblast (n¼8) suspended in 5 ml of DMEM-2% were injected through the infusion catheter. The remaining 2.5 Â 10 6 infected fibroblasts were injected into the LAD in the same manner. Plasma CK-MB was measured immediately before and 24 h after fibroblast injection to detect myocardial infarction during these procedures.
Echocardiography
Trans-thoracic echocardiography was conducted before ameroid constrictor implantation, and before and 28 days after fibroblast administration. EF was calculated from the short axis view of the left ventricle at the level of the papillary muscles.
EMM EMM was performed using the NOGA system as previously described, 12, 13 immediately before and 28 days after fibroblast administration. Briefly, a mapping catheter (NOGA-STAR, B-curve, Biosense-Webster, CA, USA) was inserted into the left ventricle, data of the endocardial movements and electrograms were collected from numerous sites (average 67710 sites in this study), and a three-dimensional endocardial LS or a UpV map was constructed. LS represents myocardial mechanical function, and UpV viability. For data analysis, the constructed left ventricular maps were divided into three segments by two planes vertical to the long axis; apex, midventricle, and base. Each segment contained 20, 40, and 40% of the length of the long axis, respectively. Then, each of the latter two segments was divided into four regions; anterior, septal, posterior, and lateral. In other words, the left ventricle was divided into nine regions. This division was performed semiautomatically by the NOGA computer, and the results were expressed as a bull's eye-like diagram (Figure 8b ).
CAG
CAG was also conducted immediately before and 28 days after fibroblast administration. First, a 6-French catheter (Britetip JL4) was inserted into the RCA, and 4.5 ml of contrast medium (Iopamiron 370, Schering, Berlin, Germany) was injected at a rate of 1.5 ml/s. Digitally subtracted images were obtained at a rate of 8 frames/s using a C-arm digital fluoroscopy system (Sirus 
RMBF
At 28 days after fibroblast administration, 7.5 Â 10 6. of dye-microspheres (Yellow Dye-Trak, Triton Technology, CA, USA) were injected into the left atrium after EMM and CAG, and RMBF was measured. A reference blood withdrawal was started 10 s prior to microsphere injection and continued for 120 s at a rate of 2.5 ml/ min. The LV myocardium was divided into 28 samples as shown in Figure 8c , and weighed (W SAMPLE ). Each sample and reference blood was digested with KOH and filtered with 10 mm pore filters to recover the microspheres. The dye was extracted from the microspheres, and absorbance at 448 nm was measured. The average blood flow rate in each of the ischemic and the nonischemic area, which were defined in the LV as shown in Figure 8c , was then calculated as (withdrawal rate) Â [(SA SAMPLE )/A BLOOD ] Â (SW SAMPLE ) -1 in the respective area, where A SAMPLE was the absorbance of the myocardial samples and A BLOOD was that of the reference blood.
Distribution of injected fibroblasts
The efficiency of fibroblast accumulation and the distribution of the accumulated fibroblasts in the LV myocardium were assessed. Fibroblasts (6.0 Â 10 Ex vivo gene transfer of basic fibroblast growth factor M Ninomiya et al infected with AxCAluc+ at 20 PFU/cell and incubated for 24 h were suspended in 12 ml of DMEM-2%, and 5 ml of this suspension containing 2.5 Â 10 6 fibroblasts was administered into each of the RCA and the LAD (10 ml in total) of pigs (n¼3) implanted with a constrictor 28 days before. The amount of luciferase in the remaining suspension (2 ml) was quantified using Luciferase Assay Kit (Promega, WI, USA), and the total amount of luciferase injected was calculated (L TOTAL ). After 2 h, the pigs were killed, and the LV myocardium was divided into 28 samples (Figure 8c ). Each sample was weighed (W SAMPLE ), and luciferase in each sample was quantified (L SAMPLE ). The percentage of fibroblasts trapped in the LV myocardium was calculated as 100 Â S(L SAMPLE ) Â (L TOTAL )
À1
. On the other hand, the concentration of the injected fibroblasts in each of the ischemic and the non-ischemic area (Figure 8c ) infected with AxCALacZ at 20 PFU/cell and incubated for 24 h were administered into each of the RCA and the LAD of normal pigs (n¼2). The pigs were killed 7 days later, and the myocardium in the inferior wall was harvested. The tissue sample was first stained with X-gal staining and then with indoxyl-tetrazolium staining.
Time course study of in vivo bFGF expression and histology
The bFGF-fibroblasts were administered to four pig models in the same fashion as described above. These pigs were killed and the myocardium in the inferior wall was harvested 4, 7, 14, and 21 days after fibroblast administration. Each myocardial tissue (0.5 g) was subjected to Western blot analysis. Tissue samples obtained from the inferior wall and the lateral wall of the same pig were stained with hematoxylin and eosin staining and inspected.
Statistical analysis
Results were expressed as mean7s.d. Data measured at one time point were compared between the bFGF and the control groups using the unpaired t-test. As for data measured at two time points (before and after fibroblast injection) in the 'echocardiography', 'EMM', and 'CAG', the increments were compared between the bFGF and the control groups using the unpaired t-test (echocardiography and EMM) or Wilcoxon's rank sum test (CAG). In the 'EMM', Fisher's combination test was conducted for evaluating global significance in nine LV regions with control of multiplicity. Namely, À2 Â Slog (P) (P: P-value corresponding to group difference in each of the nine LV regions) was calculated and evaluated using w 2 (degree of freedom¼18). In the
